AMGN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

9.46B

+4.09%

4.743

-10.67%

8.66B

+6.23%

5.041

+2.88%

9.29B

+1.18%

5.741

-4.64%

Estimates Revision

The market is revising No Change the revenue expectations for Amgen Inc. (AMGN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 19.12%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+19.12%

In Past 3 Month

19 Analyst Rating

Wall Street analysts forecast AMGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMGN is 328.25 USD with a low forecast of 272.00 USD and a high forecast of 389.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

10 Hold

1 Sell

Moderate Buy

Current: 325.310

Low

272.00

Averages

328.25

High

389.00

Current: 325.310

Low

272.00

Averages

328.25

High

389.00

Morgan Stanley

Equal Weight

downgrade

$329 -> $304

2025-12-12

New

Reason

Morgan Stanley

Price Target

$329 -> $304

2025-12-12

New

downgrade

Equal Weight

Reason

Morgan Stanley lowered the firm's price target on Amgen to $304 from $329 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.

HSBC

Buy

maintain

$381 -> $425

2025-12-10

Reason

HSBC

Price Target

$381 -> $425

2025-12-10

maintain

Buy

Reason

HSBC raised the firm's price target on Amgen to $425 from $381 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."

Erste Group

Hold

Buy

upgrade

2025-12-05

Reason

Erste Group

Price Target

2025-12-05

upgrade

Hold

Buy

Reason

Erste Group upgraded Amgen to Buy from Hold. The firm says Amgen has a higher operating margin and return on equity than the sector average. In addition, the company's MariTide is the first obesity treatment with monthly or less frequent dosing to demonstrate safe weight loss in a Phase 2 study, the analyst tells investors in a research note. Erste sees a "favorable" valuation at current share levels.

BMO Capital

Evan Seigerman

Outperform

maintain

$335 -> $372

2025-12-03

Reason

BMO Capital

Evan Seigerman

Price Target

$335 -> $372

2025-12-03

maintain

Outperform

Reason

BMO Capital analyst Evan Seigerman raised the firm's price target on Amgen to $372 from $335 and keeps an Outperform rating on the shares. The company's MariTide Phase 2 Part 2 data has the potential to drive share strength beyond the commercial performance seen from Amgen in 202 as they represent the key remaining clinical update for Amgen in 2025 and could provide a view of MariTide's potential as a maintenance therapy, the analyst tells investors in a research note. BMO's higher price target reflects a higher probability of success for MariTide and benefits the stock has seen from an improving macro environment, the firm added.

Truist

Hold

initiated

$298 -> $318

2025-11-24

Reason

Truist

Price Target

$298 -> $318

2025-11-24

initiated

Hold

Reason

Truist assumed coverage of Amgen with a Hold rating with a price target of $318, up from $298. The firm views the stock as a defensive biotech with a stable revenue base, though challenged by key franchises' upcoming patent expiries over the coming decade, the analyst tells investors in a research note. Amgen's emerging products and pipeline hold high clinical potential, but visibility into their ability to offset base business erosion remains limited, the firm added.

Piper Sandler

Overweight

maintain

$342 -> $381

2025-11-14

Reason

Piper Sandler

Price Target

$342 -> $381

2025-11-14

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on Amgen to $381 from $342 and keeps an Overweight rating on the shares. The firm notes monthly third-party prescription data for October 2025 became available recently, and this piece highlights Rx data and trends for a number of key Amgen products. Looking at Repatha and Tezspire more specifically, Piper continues to believe that visibility into aggressive volume growth for both products is high.

Valuation Metrics

The current forward P/E ratio for Amgen Inc (AMGN.O) is 15.36, compared to its 5-year average forward P/E of 14.03. For a more detailed relative valuation and DCF analysis to assess Amgen Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

14.03

Current PE

15.36

Overvalued PE

15.11

Undervalued PE

12.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

10.18

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

11.10

Undervalued EV/EBITDA

9.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.76

Current PS

0.00

Overvalued PS

5.16

Undervalued PS

4.37

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 876.66% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 876.66% over the last month.

Sold

Bought

AMGN News & Events

Events Timeline

No data

News

9.0

12-15Benzinga

Argenx Suspends Phase 3 Trial for Thyroid Eye Disease, Opening Opportunities for Competitors Like Viridian Therapeutics

4.5

12-15NASDAQ.COM

Dow Stocks in Focus: CRM, GS

8.0

12-15NASDAQ.COM

7 Dividend ETFs to Invest $2,000 in for Long-Term Holding – Featuring the Schwab U.S. Dividend Equity ETF (SCHD)

People Also Watch

Frequently Asked Questions

What is Amgen Inc (AMGN) stock price today?

The current price of AMGN is 325.31 USD — it has increased 2.38 % in the last trading day.

What is Amgen Inc (AMGN)'s business?

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

What is the price predicton of AMGN Stock?

What is Amgen Inc (AMGN)'s revenue for the last quarter?

Amgen Inc revenue for the last quarter amounts to 9.56B USD, increased 12.40 % YoY.

What is Amgen Inc (AMGN)'s earnings per share (EPS) for the last quarter?

Amgen Inc. EPS for the last quarter amounts to 5.93 USD, increased 13.60 % YoY.

What changes have occurred in the market's expectations for Amgen Inc (AMGN)'s fundamentals?

How many employees does Amgen Inc (AMGN). have?

Amgen Inc (AMGN) has 28000 emplpoyees as of December 16 2025.

What is Amgen Inc (AMGN) market cap?

Today AMGN has the market capitalization of 175.17B USD.